1. Publications
Dennis Huszar
1. Huszar D, and Bacchetti S. Partial purification and characterization of the
ribonucleotide reductase induced by herpes simplex virus infection of mammalian
cells. J. Virol. 37: 580-588, 1981.
2. Huszar D, and Bacchetti S. Is ribonucleotide reductase the transforming function
of herpes simplex virus 2? Nature 302: 76-79, 1983.
3. Huszar D, Beharry S, and Bacchetti S. Herpes simplex virus-induced
ribonucleotide reductase: development of antibodies specific for the enzyme. J.
Gen. Virol: 64: 1327-1335, 1983.
4. Bacchetti S, Evelegh MJ, Muirhead B, Sartori CS, and Huszar D. Immunological
characterization of herpes simplex virus type 1 and 2 polypeptides involved in
ribonucleotide reductase activity. J. Virol. 49: 591-593, 1984.
5. Dick J, Magli MC, Huszar D, Phillips RA, and Bernstein A. Introduction of a
selectable gene into primitive stem cells capable of long-term reconstitution of
the hemopoietic system of W/Wv mice. Cell 42: 71-79, 1985.
6. Huszar D, Balling R, Kothary R, Magli MC, Hozumi N, Rossant J and Bernstein
A. Insertion of a bacterial gene into the mouse germ line using an infectious
retrovirus vector. Proc. Natl. Acad. Sci. USA 82: 8587-8591, 1985.
7. Wu DD, Huszar D, Dick J, Bernstein A, and Phillips R A. High efficiency gene
transfer and expression in normal murine B lymphocytes. J. Immunol. Methods
101: 279-285, 1987.
8. Magli MC, Dick J, Huszar D, Bernstein A, and Phillips RA. Modulation of gene
expression in multiple hematopoietic cell lineages following retroviral vector gene
transfer. Proc. Natl. Acad. Sci. USA 84: 789-793, 1987.
9. Huszar D, Ellis J, and Bernstein A. A rapid and accurate method for determining
the titer of retrovirus vectors lacking a selectable marker. Technique 1: 28-32,
1989.
10. Bennett DC, Huszar D, Laipis PJ, Jaenisch R, and Jackson IJ. Phenotypic
rescue of mutant brown melanocytes by a retrovirus carrying a wild-type
tyrosinase-related protein gene. Development 110: 471-475, 1990.
11. Huszar D, Sharpe A, and Jaenisch R. Migration and proliferation of cultured
neural crest cells in W mutant neural crest chimeras. Development 112: 131-141,
1991.
12. Huszar D, Sharpe A, Hashmi S, Bouchard B, Houghton A, and Jaenisch R.
Generation of pigmented stripes in albino mice by retroviral marking of neural
crest melanoblasts. Development 113: 653-660, 1991.

2. 13. Chen J, Trounstine M, Kurahara C, Young F, Kuo CC, Xu Y, Loring JFL, Alt FW,
and Huszar D. B cell development in mice that lack one or both immunoglobulin
kappa light chain genes. EMBO J. 12: 821-830, 1993.
14. Chen J, Trounstine M, Kurahara C, Young F, Kuo CC, Xu Y, Loring JFL, Alt FW,
and Huszar D. Generation of a B cell-deficient mouse by targeted deletion of
immunoglobulin JH gene segments. Int. Immunol. 5: 647-656, 1993.
15. Kim JY, Kurtz B, Huszar D, and Storb U. Crossing the SJL lambda locus into -
knockout mice reveals a dysfunction of the lambda 1-containing immunoglobulin
receptor in B cell differentiation. EMBO J. 13: 827-834, 1994.
16. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR,
Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O'Regan D, O'Donnell
SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM, and
Huszar D. Antigen-specific human antibodies from mice comprising four distinct
genetic modifications. Nature 368, 856-859, 1994.
17. Taylor LD, Carmack CE, Huszar D, Higgins KM, Mashayekh R, Sequar G,
Schramm SR, Kuo CC, O'Donnell SL, Kay RM, Woodhouse CS, and Lonberg N.
Human immunoglobulin transgenes undergo rearrangement, somatic mutation
and class switching in mice that lack endogenous IgM. Int. Immunol. 6, 579-591,
1994.
18. van der Heyde HC, Huszar D, Woodhouse C, Manning DD, and Weidanz WP.
The resolution of acute malaria in a definitive model of B cell deficiency, the JHD
mouse. J. Immunol. 152, 4557-4562, 1994.
19. Cable J, Huszar D, Jaenisch R, and Steel KP. Effects of mutations at the W
locus (c-kit) on inner ear pigmentation and function in the mouse. Pigment Cell
Res. 7, 17-32, 1994.
20. Shlomchik MJ, Madaio MP, Ni D, Trounstine M, and Huszar D. The role of B
cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180, 1295-1306, 1994.
21. Luning Prak E, Trounstine M, Huszar D, and Weigert M. Light chain editing in -
deficient animals: a potential mechanism of B cell tolerance. J. Exp. Med. 180,
1805-1815, 1994.
22. Pricop L, Brumeanu T, Elahi E, Moran T, Wang BS, Trounstine M, Huszar D, Alt
F, and Bona C. Antibody response elicited by T-dependent and T-independent
antigens in gene targeted -deficient mice. Int. Immunol. 6: 1839-1847, 1994.
23. Chen C, Nagy Z, Radic MZ, Hardy RR, Huszar D, Camper SA, and Weigert M.
The site and stage of anti-DNA B-cell deletion. Nature 373: 252-255, 1995.
24. Liu Y, Wu Y, Ramarathinam L, Guo Y, Huszar D, Trounstine M, and Zhao M.
Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell
response. Int.Immunol. 7: 1353-1362, 1995.

3. 25. Engelward B, Dreslin A, Christensen J, Huszar D, Kurahara C, and Samson L.
Repair deficient 3-methyladenine DNA glycosylase homozygous mutant mouse
cells have increased sensitivity to alkylation-induced chromosome damage and
cell killing. EMBO J. 15: 945-952, 1996.
26. Farese RV Jr, Veniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, Traber M,
Ruland S, Stokowski RS, Huszar D, and Young SG. Phenotypic analysis of
mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc.
Natl. Acad. Sci. U.S.A. 93: 6393-6398, 1996.
27. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier
LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn .
and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity
in mice. Cell 88: 131-141, 1997.
28. Kesterson RA, Huszar D, Lynch CA, Simerly RB, and Cone RD. Induction of
neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in
two models of the agouti obesity syndrome. Molecular Endocrinology 11: 630-
637, 1997.
29. Varban ML, Rinninger F, Wang N, Fairchild-Huntress V, Dunmore JH, Fang Q,
Gosselin ML, Dixon KL, Deeds JD, Acton SL, Tall AR, and Huszar D. Targeted
Mutation Reveals a Central Role for SR-BI in Hepatic Selective Uptake of HDL
Cholesterol. Proc. Natl. Acad. Sci. USA 95: 4619-4624, 1998.
30. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, Burn P,
and Palmiter RD. Response of melanocortin-4 receptor-deficient mice to
anorectic and orexigenic peptides. Nat. Gen. 21: 119-122, 1999.
31. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault BJ, DiRocco L, Holmgren L,
Montagno J, Bork P, Huszar D, Fairchild-Huntress V, Ge P, Keilty J, Ebeling C,
Baldini L, Gilchrist J, Burn P, Carlson GA., and Moore KJ. The mahogany protein
is a receptor involved in suppression of obesity. Nature 398: 148-152, 1999.
32. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang CP, Chen W, Seo T,
Deckelbaum R, Huszar D, and Tall AR. Decreased selective uptake of HDL
cholesteryl esters in apolipoprotein E knock-out mice. Proc. Natl. Acad. Sci. USA.
96: 12050-12055, 1999.
33. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, and Tall AR.
Hepatic scavenger receptor BI promotes rapid clearance of HDL free cholesterol
and transport into bile. J. Biol. Chem. 274: 33398-333402, 1999.
34. Stubdal H, Lynch CA, Moriarty A, Fang Q, Chickering T, Deeds JD, Fairchild-
Huntress V, Charlat O, Dunmore JH, Klein P, Huszar D, and Kapeller R.
Targeted deletion of the tub mouse obesity gene reveals that tubby is a loss-of-
function mutation. Mol. Cell Biol. 20: 878-882, 2000.

4. 35. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-
Huntress V, Dixon K, Dunmore JH, Gimbrone MA, Falb D. and Huszar D. A role
for Smad6 in development and homeostasis of the cardiovascular system.
Nature Genetics 24: 171-174, 2000.
36. Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild-Huntress V,
Donovan MJ and Tall AR. Increased LDL cholesterol and atherosclerosis in LDL
receptor-deficient mice with attenuated expression of scavenger receptor B1.
Arteriosclerosis, Thrombosis and Vascular Biology 20:1068-1073, 2000.
37. Auerbach W, Dunmore JH, Fairchild-Huntress V, Fang Q, Auerbach AB, Huszar
D, and Joyner AL. Establishment and chimera analysis of 129 SvEv- and
C57BL/6-derived mouse embryonic stem cell lines. BioTechniques 29: 1024-
1032, 2000.
38. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-
Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y. Mice deficient in fractalkine
are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol.
125: 59-65, 2002.
39. Gozgit, JM, Bebernitz G, Patil P, Ye M, Wu J, Su N, Wang T, Ioannidis S, Davies
A, Huszar D, and Zinda M. Effects of the JAK2 inhibitor, AZ960, on
Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J,
Biol. Chem. 283: 32334-32343, 2008.
40. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner
R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye
M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S,
McCoon P, Cao ZA, Yu H, Jove R, and Zinda M. The JAK2 Inhibitor, AZD1480,
Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell
16: 487-497, 2009.
41. Ioannidis S, Wang T, Lamb ML, Su M, Almeida L, Davies AM, Zhang HJ, Read
J, Hoffmann E, Rivard C, Bell K, Bebernitz G, Alimzhanov A, Huszar D, and
Zinda, M. Discovery and pre-clinical evaluation of (S)-5-chloro-N2
-(1-(5-
fluoropyrimidin-2-yl)ethyl)-N4
-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
(AZD1480) as a novel JAK2 Inhibitor. J. Med. Chem. 54: 262-276, 2011.
42. Kantarjian H, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina
A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala
K, Odenike T, Altman JK, and Minden M. Phase I/II multicenter study to assess
the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in
patients with refractory acute myeloid leukemia. Invest New Drugs, e-pub. April
15, 2011.
43. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik
JM, Hylander-Gans L, Osmukhina A, Huszar D, and Herbst RS. A Phase I study
to assess the safety, tolerability, and pharmacokinetics of AZD4877, an
intravenous Eg5 inhibitor in patients with advanced solid tumours. Cancer
Chemother Pharmacol 69:165-172, 2011.

5. 44. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W,
Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, and
Yu H. Anti-angiogenic and anti-metastatic activity of JAK inhibitor AZD1480.
Cancer Res, 71: 6601-6610, 2011.
45. Theoclitou ME, Aquila B, Block MH, Brassil PJ, Castriotta L, Code E, Collins M,
Davies AM, Deegan T, Ezhuthachan J, Filla S, Freed E, Hu H, Huszar D,
Jayaraman M, Lawson D, Lewis PM, Nadella MVP, Oza V, Padmanilayam M,
Pontz T, Ronco L, Russell D, Whitston D, and Zheng X. Discovery of (+) N-(3-
Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-
methylpropyl]-4-methylbenzamide (AZD4877),a kinesin spindle protein inhibitor
and potential anticancer agent. J Med Chem 54: 6734-6750, 2011.
46. McFarland BC, Ma JY, Langford CP, Gillespie Y, Yu H, ZhengY, Nozell SE,
Huszar D, and Benveniste EN. Therapeutic Potential of AZD1480 for the
Treatment of Human Glioblastoma. Mol Cancer Ther, 10:2384-2393, 2011.
47. Loveless ME, Lawson D, Collins M, Nadella MVP, Reimer C, Huszar D, Halliday
J, Waterton JC, Gore JC, and Yankeelov TE. Comparisons of the Efficacy of a
Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (cediranib) and Sham
Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology.
Neoplasia 14:54-64, 2012.
48. Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu, K, You Z,
Huszar D, Skolnik JM, and Schwartz GK. A Phase I trial of the Kinesin Spindle
Protein (Eg5) Inhibitor AZD4877 in Patients with Solid and Lymphoid
Malignancies. Invest New Drugs published online May 22, 2012.
49. Marquis L, Tran M, Choi W, Lee I, Huszar D, Siefker-Radtke A, Dinney CP, and
McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor
AZD4877 in bladder cancer cells. Cancer Biol & Therapy 13:1-10, 2012.
50. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen
T, Granitto S, Zhang X, Cotari J, Alpaugh ML, Stanchina E, Manova K, Li M,
Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton
L, Nishimoto N, Huszar D, Lyden D, and Bromberg J. The IL-6/JAK/Stat3 Feed-
Forward Loop Drives Tumorigenesis and Metastasis. Neoplasia, 15:848-862,
2013.
51. Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati
P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue PA, Gomella L, Huszar D,
Nevalainen MT. Pharmacological inhibition of Jak2-STAT5 signaling by Jak2
inhibitor AZD1480 potently suppresses growth of both primary and castrate-
resistant prostate cancer. Clin Cancer Res, 19:5658-74, 2013.
52. Su Q, Ioannidis S, Chuaqui C, Almeida L, Alimzhanov M, Bebernitz G, Bell K,
Block M, Howard T, Huang S, Huszar D, Read J, Rivard Costa C, Shi J, Su M,
Ye M, Zinda M. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2
inhibitors. J Med Chem, 57:144-58, 2014.

6. 53. Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur
S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM,
DeAngelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D. AZD1208, a
potent and selective pan-PIM kinase inhibitor, demonstrates efficacy in preclinical
models of acute myeloid leukemia. Blood, 123:905-913, 2014.
54. Stuart EC,BuchertM, PutoczkiT, Thiem S, Farid R, ElzerJ, Huszar D, Waring
PM, PhesseTJ, ErnstM. Therapeutic inhibition of Jak activity inhibits progression
of gastrointestinal tumors in mice. Molecular Cancer Therapeutics, 13:468-474,
2014.
55. Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B,
Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.
Pharmacological suppression of Jak1/2 by Jak1/2 inhibitor AZD1480 potently
inhibits IL-6-induced experimental prostate cancer metastases formation.
Molecular Cancer Therapeutics, 13:1246-1258, 2014.
56. Meja K, Stengel C, Huszar D, Davies BR, Gale RE, Linch DC, Khwaja A. PIM
and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid
leukaemia which is associated with convergence on mTOR and MCL1 pathways.
Br J Hematol, 167:69-79, 2014.
57. PhesseTJ, Buchert M, Stuart E, Flanagan DJ, Faux M, Afshar-Sterle S, WalkerF,
Zhang HH, Nowell CJ, Jorrisen R, Tan CW, Hirokawa Y, Eissmann MF, Poh AR,
Malaterre J, Pearson HB, Kirsch DG, Provero P, Poli V, RamsayRG, Sieber O,
Burgess AW, HuszarD, Vincan E, Ernst M. Partial inhibition of gp130-Jak-Stat3
signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and
regeneration. Science Signaling, 7:ra92, 2014.
58. KirschnerAN, WangJ, van der Meer R, Anderson PD, Franco-Coronel OE,
KushnerMH, Everett JH, Hameed O, Keeton EK, Huszar D, Abdulkadir SA. PIM
kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl.
Cancer Inst. Dec 107:2014
59. Gao SP, Mao N, Bournazou I, Daly LA, Schori L, Pao W, Ladanyi M, Manova K,
Levine RL, Vogel R, Altan-Bonnet G, Norton L, Soli D, Rosen N, Smith PD, Zinda
M, Huszar D, Lyden D, Bromberg J. Negative feedback regulation of EGFR by
JAK2 in NSCLC. Submitted, PNAS.
60. Gritsina G, Xiao F, O’Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ,
Zhou Y, Litwin S, Balachandran S, Sigal LJ, Huszar D and Connolly DC.
Targeted inhibition of the JAK/STAT3 pathway inhibits ovarian carcinoma growth.
Submitted, Mol Cancer Therapeutics
61. Natarajan K,Mathias TJ, Doshi K, Tron, Kraus M, Trotta R,Perrotti D,Huszar D,
Baer MR. The Pim kinase inhibitor AZD1208 enhances apoptosis induction by
clinically active FLT3 inhibitors in FLT3-ITD acute myeloid leukemia cells in vitro
and in vivo through synergistic downregulation of Mcl-1 and of Bcl-xL. Manuscript
in preparation

7. 62. McEachern KA, Tron AE, O’Connor G, DuPontR, Gibbons FD, Pablo
L,Vishwanathan K, McCoon P, Cortes J, DeAngelo DJ, Minden M, Uy GL,
Neumann F, Keating K, Huszar D, Pease E, Brown JL and Barrett JC. Preclinical
and clinical pharmacodynamics of pan-Pim inhibition by AZD1208 in Acute
Myeloid Leukemia: assessment of Pim isoform dependency for BAD and 4EBP1
phosphorylation. Manuscript in preparation
Invited Contributions
63. Bernstein A, Berger S, Huszar D. and Dick J. Gene transfer with retrovirus
vectors. In:
Genetic Engineering: Principles and Methods, vol. 7, (J. K. Setlow and A.
Hollaender, eds.)
(New York: Plenum Press) pp. 235-261, 1985.
64. Bernstein A, Dick J, Huszar D, Robson I, Rossant J, Magli MC, Estrov Z,
Freedman M. and Phillips RA. Genetic engineering of mouse and human stem
cells. Cold Spring Harbor Symp. Quant. Biol. 51: 1083-1091, 1986.
65. Lonberg N. and Huszar D. Human antibodies from transgenic mice. Int. Rev.
Immunol. 13: 65-93, 1995.
66. Huszar D, Theoclitou ME, Skolnik J, and Herbst R. Kinesin Motor Proteins as
Targets for Cancer Therapy. Cancer and Metastasis Reviews 28: 197-208, 2009.
Guest Editor, International Reviews of Immunology “Lymphocyte Development in Gene
Targeted Mutant Mice” volume 13, number 1, Harwood Academic Publishers, 1995.